Association of breast cancer risk, density, and stiffness: global tissue stiffness on breast MR elastography (MRE)

Bhavika K. Patel1, Kay Pepin2, Kathy R. Brandt2, Gina L. Mazza3, Barbara A. Pockaj4, Jun Chen2, Yuxiang Zhou1, Donald W. Northfelt5, Karen Anderson5, Juliana M. Kling6, Celine M. Vachon7, Kristin R. Swanson8, Mehdi Nikkhah9,10, Richard Ehman2

Abstract

Purpose Quantify in vivo biomechanical tissue properties in various breast densities and in average risk and high-risk women using Magnetic Resonance Imaging (MRI)/MRE and examine the association between breast biomechanical properties and cancer risk based on patient demographics and clinical data.

Methods Patients with average risk or high-risk of breast cancer underwent 3.0 T breast MR imaging and elastography. Breast parenchymal enhancement (BPE), density (from most recent mammogram), stiffness, elasticity, and viscosity were recorded. Within each breast density group (non-dense versus dense), stiffness, elasticity, and viscosity were compared across risk groups (average versus high). Separately for stiffness, elasticity, and viscosity, a multivariable logistic regression model was used to evaluate whether the MRE parameter predicted risk status after controlling for clinical factors.

Results 50 average risk and 86 high-risk patients were included. Risk groups were similar in age, density, and menopausal status. Among patients with dense breasts, mean stiffness, elasticity, and viscosity were significantly higher in high-risk patients (N = 55) compared to average risk patients (N = 34; all p < 0.001). Stiffness remained a significant predictor of risk status (OR = 4.26, 95% CI [1.96, 9.25]) even after controlling for breast density, BPE, age, and menopausal status. Similar results were seen for elasticity and viscosity.

Conclusion A structurally based, quantitative biomarker of tissue stiffness obtained from MRE is associated with differences in breast cancer risk in dense breasts. Tissue stiffness could provide a novel prognostic marker to help identify high-risk women with dense breasts who would benefit from increased surveillance and/or risk reduction measures.

Keywords Breast cancer risk · Dense breasts · Breast tissue stiffness · Breast MR imaging · Breast elastography · Breast stroma
Introduction and background

Fifty percent of screening-eligible women have high mammographic breast density (MBD). MBD is a strong risk factor for breast cancer, with a four to sixfold increased risk in women with dense tissue compared to those with minimal dense tissue [1]. As such, increased areas of breast density may be more susceptible to the initiation and promotion of breast cancers. However, breast cancer risk is not elevated across all women with dense breasts uniformly [2].

Because half of all women have dense breast tissue, there is significant interest in developing imaging biomarkers to improve personalized risk stratification and identify which women with dense breasts are, in fact, at elevated risk for breast cancer. Doing so will enable appropriate imaging surveillance, reduce unnecessary additional screening, and enable effective risk-reducing strategies for women with dense breasts.

Studies have shown that the variation in the risk associated with breast density may be related to differences in the breast microenvironment at a microscopic level [3–6]. More recently, studies using quantitative proteomics, collagen analyses, and mechanical measurements have demonstrated that mammographically dense tissues have varying levels of collagen density, breast stroma stiffness, and epithelial cell density [7–9]. These mechanical properties of tissue play a major role in the development and progression of disease states and have been studied in multiple parts of the body [10–12]. Preliminary studies, performed in vitro, in animal models, or in small numbers of patients (livers and other organs), show this hypothesis to be true and also valid in relation to breast cancer development. An in vivo study in mice [13] demonstrated a causal link between increased stroma collagen deposition and enhanced tumorigenesis, local invasion, and metastases. These interactions may, in turn, affect oncogenesis and contribute to increased cancer risk in dense breasted women [4, 14, 15].

With the advent of MR elastography, quantitative biomechanical properties, such as tissue stiffness, elasticity and viscosity, have become viable imaging biomarkers to better understand the tissue microenvironment of patients in vivo [16–19]. Magnetic resonance elastography (MRE) is a safe and novel non-invasive imaging technique to quantitatively assess the mechanical properties of soft tissues using MR imaging. It assesses the viscoelastic shear properties of lesions through direct MR visualization of acoustic waves and demonstrates decreased elasticity in malignant tumors. The key component of elasticity imaging is to characterize the tissue response to the stress. In general, MRE imaging consists of the following steps: (1) Deliver shear waves in the tissues to be imaged; (2) Measure tissue displacement; (3) Generate quantitative stiffness maps (elastograms). As such, MRE allows an objective, quantitative analysis of the viscoelastic properties of average and diseased breast tissues, providing greater insight into the study of and treatment of breast cancer and may be used to differentiate which dense breasts will go on to develop cancer. We hypothesize that the distinctive biomechanical properties of microenvironments can be assessed by MRE, and may account for the varying risk patterns for breast cancer in patients with similar densities. In this study, we will quantify in vivo biomechanical tissue properties, such as breast stiffness, elasticity and viscosity, in various breast densities in both average risk and high-risk women using Magnetic Resonance Imaging (MRI)/MRE. We will also examine the association of biomechanical properties of the breast with cancer risk based on patient demographic and clinical data.

Materials and methods

Patients

In this institutional review board-approved prospective single-institution study, we recruited two groups of women with all breast densities with different breast cancer risks to undergo a 3.0 T dynamic contrast-enhanced MRI/MRE of the breast. Average risk women were defined as having no personal history of breast cancer, no prior high-risk breast biopsies, no self-reported significant family history of breast cancer, and a negative mammogram within 12 months (Table 1). Average risk patients were at least 35 years old, not pregnant, not breastfeeding, had no imaging abnormality on mammography or sonography (Breast Imaging Reporting and Data System [BI-RADS] 1 or 2), and had no contraindications to MRI or contrast agents. These patients enrolled in the trial received a research-only MRI with MRE.

High-risk breast cancer patients were recruited from patients who received standard of care breast MR for routine evaluation (patients with prior breast cancer history or those who were deemed at lifetime risk of 20% or greater based on Tryir Czuick scores [20–23]). All prospectively collected patients provided informed written consent. High-risk patients were at least 26 years of age, not pregnant, not breastfeeding, had no imaging abnormality on mammography or sonography (Breast Imaging Reporting and Data System [BI-RADS] 1 or 2), and had no contraindications to MRI or contrast agents.

Exclusion criteria were incomplete examinations and technical failures.
All patients received combined 3-T multiparametric contrast-enhanced breast MRI and breast elastography.

**Breast MRE protocol**

Our breast MRE exam is naturally integrated into the established breast CEMRI / MRI clinical protocol, avoiding the need to switch RF coils or reposition patients. Our current breast MRE protocol was previously published [24], and the breast MRE sequence is added at the conclusion of the clinical portion of the exam.

The breast MRE protocol is performed using a gradient echo phase contrast sequence [25]. A pillow-like passive driver is positioned between the breasts under the sternum while the patient lies prone in a standard breast coil [24]. Low-frequency vibrations of 40 Hz are transmitted to the passive driver from an active driver (Resoundant, Inc., Rochester, MN) located outside the scan room during the entire duration of image acquisition (5–7 min). Breast MRE data are obtained from 40 axial slices, centered at the breast along the superior-inferior direction. A modified 3D-GREMRE pulse sequence is used with the following major parameters [9]: vibration frequency = 40 Hz; FOVx/y/z = 38.4/38.4/12 cm; flip angle = 8°; TR = 22.2–22.9 ms, TE = 15.9–18.1 ms (fat/water in-phase); axial bilateral imaging plane; matrix = 96 × 96 × 30; 8 motion cycles per 9 TRs (3 phase offsets); motion sensitivity (MENC) = 12.3 micron/radian; motion encoding directions = x/y/z; scan time = 5°25”−5°42” (free breathing). 3D wave images are processed with 3D multiple-model direct inversions without directional filtering, generating 3D elastograms of bilateral breasts.

**Breast MRE measurements**

Regions of interest are then drawn over the central slice (at the level of the nipple) and custom, in-house software is used to obtain MRE stiffness values. Quantitative breast stiffness and viscosity measurements were obtained as described previously [24] by drawing the whole breast region of interest (ROI) around the breast tissue (at the center slice). This was drawn on the magnitude images, which demonstrate anatomy the best. The wave images were analyzed to assess the adequacy of wave penetration through breast tissue. The ROI was then copied and translated onto the stiffness and viscosity maps to obtain the global breast MRE measurement.

**Multiparametric breast MRI**

A dynamic contrast-enhanced image set was also acquired, with the first series being an unenhanced fat-saturated gradient-recalled echo T1-weighted sequence (VIBRANT) followed by three dynamic contrast-enhanced fat-saturated T1-weighted gradient-recalled echo series (VIBRANT) performed after IV administration of Gadobutrol (Gadavist, Bayer) at 30 s, 3 min and 6 min with the use of a T1-weighted dosing protocol. The dynamic contrast images were acquired in the sagittal orientation (TR/TE = 5.1/2.4 ms; matrix = 256 × 256). Automatic post-processing included the generation of subtraction images between pre- and post-contrast images produced after each phase. Late gadolinium fat-suppressed T1-weighted fast-spoiled-gradient-echo (FSPGR) sequences were also acquired for both right and left sides separately in the axial orientation (TR/TE = 115/3.15 ms; matrix = 256 × 192, NEX = 2). T2 weighted sagittal and T1 weighted FSE AX images were obtained pre-contrast.

---

**Table 1** Patient demographic characteristics by risk status

| Characteristic                        | Average risk (N = 50) | High risk (N = 86) | Total (N = 136) | p-value* |
|--------------------------------------|-----------------------|--------------------|-----------------|----------|
| Age in years (mean, SD)              | 55.6 (10.2)           | 53.6 (11.3)        | 54.3 (10.9)     | 0.27     |
| Breast density (#, % dense)          | 34 (68.0%)            | 55 (64.0%)         | 89 (65.4%)      | 0.71     |
| Prior breast cancer (#, % yes)       | 0 (0.0%)              | 28 (32.6%)         | 28 (20.6%)      | —        |
| Biopsy-proven high risk lesion (#, % yes) | 0 (0.0%)              | 12 (14.0%)         | 12 (8.8%)       | —        |
| Biopsy or surgery in either breast (#, % yes) | 7 (14.0%)              | 50 (58.1%)         | 57 (41.9%)      | < 0.001  |
| Menopausal status (#, % post-menopausal) | 33 (66.0%)            | 60 (69.8%)         | 93 (68.4%)      | 0.70     |
| On hormone replacement therapy (#, % yes) | 5 (10.0%)              | 8 (9.3%)           | 13 (9.6%)       | > 0.999  |
| First degree relative with breast cancer (#, % yes) | 0 (0.0%)              | 64 (74.4%)         | 64 (47.1%)      | —        |

*For age in years, the p-value was based on a two-sample t-test allowing for unequal variances. For all other patient demographic and disease characteristics, the p-value was based on Fisher’s exact test. Em dashes indicate that the p-value was not calculated because high-risk status was defined by prior breast cancer, biopsy-proven high-risk lesion, and family history of breast cancer
Statistical analysis

In both the average risk and high-risk groups, the following breast imaging features were recorded: breast parenchymal enhancement (BPE) (from clinical breast MR imaging report); breast density (from most recent clinical MG report); tissue stiffness, elasticity, and viscosity. Breast background parenchymal enhancement was routinely assessed on a BIRADS scale [26] (minimal, mild, moderate, marked) by standard of care within the imaging reports by one of five breast fellowship trained radiologists. Patient demographic and disease characteristics were summarized for the full sample and by risk status; comparisons were conducted across risk groups (average versus high) using two-sample t-tests (for continuous variables) or Fisher’s exact test (for categorical variables). Breast stiffness, elasticity, or viscosity was missing for one breast, then the value observed for the contralateral breast was used. For the full sample and within each breast density group (non-dense versus dense), two-sample t-tests allowing for unequal variances were conducted to compare breast stiffness, elasticity, and viscosity across risk groups (average versus high). Separately for breast stiffness, elasticity, and viscosity, a multivariable logistic regression model was used to evaluate whether the MRE parameter predicted risk status after controlling for clinical factors. A nominal significance level of $\alpha = 0.05$ was used for all analyses.

Results

Patients

From February 2017 to November 2019, 57 average risk and 86 high-risk patients were recruited to the study. Of the 57 average risk patients, 50 who met the inclusion criteria were included in the average risk portion of the study (mean age = 55.6 years, range = 39.0–74.0; Table 1); 2 were excluded for incomplete examinations, and 5 were excluded for technical failures. All 50 average risk patients had breast stiffness, elasticity, and viscosity data available for both breasts. Eighty-six patients who fulfilled the inclusion criteria were included in the high-risk portion of the study (mean age = 53.6 years, range = 26.0–76.0; Table 1). Of these 86 high risk patients, 82 had breast stiffness, elasticity, and viscosity data available for both breasts, and 4 had these data available for one breast.

As shown in Table 1, average risk and high-risk women did not significantly differ in their mean age (mean age = 55.6 vs. 53.6 years, $p = 0.27$), density (68.0% vs. 64.0% dense breasts, $p = 0.71$), or menopausal status (66.0% vs. 69.8% were post-menopausal, $p = 0.70$).

Breast MRI BPE measurements

Background parenchymal enhancement was stratified into two cohorts on MRI (minimal or mild versus moderate or
marked) and did not significantly differ between the average risk and high-risk cohorts, \( p = 0.56 \).

**Breast MRE measurements**

Quantitative breast stiffness and viscosity measurements were significantly higher in the high-risk dense breast cohort (\( N = 55 \)) compared to that of the average risk dense breast cohort (\( N = 34 \); all \( p < 0.001 \)) (Figs. 1, 2).

The means were not significantly different between those with dense versus non-dense breasts in the average risk patient cohort (\( p = 0.14 \) for breast stiffness, \( p = 0.78 \) for breast viscosity; Table 2). Similarly, the means were not significantly different between those with dense versus non-dense breasts in the high-risk patient cohort (\( p = 0.09 \) for breast stiffness, \( p = 0.13 \) for breast viscosity; Table 2, Fig. 3). In the 40 women who had a prior breast surgery or biopsy on one breast but not the other, breast stiffness did not significantly differ between those with dense versus non-dense breasts in either risk cohort.

---

**Table 2** Magnetic resonance elastography (MRE) parameters and Magnetic Resonance Imaging (MRI) background parenchymal enhancement (BPE) by risk status and breast density

| Characteristic          | Average risk |                   |                   | High risk |                   |                   |
|-------------------------|--------------|-------------------|-------------------|-----------|-------------------|-------------------|
|                         |              | Non-dense (\( N = 16 \)) | Dense (\( N = 34 \)) |                   | Non-dense (\( N = 31 \)) | Dense (\( N = 55 \)) |
| Breast stiffness        |              |                   |                   | p-value\(^a\) |                   |                   |
| Mean (SD)               | 1.07 (0.18)  | 1.16 (0.21)       |                   | 1.69 (1.19)  | 2.14 (1.12)       |                   |
| Median (range)          | 1.05 (0.65–1.44) | 1.15 (0.76–1.67) |                   | 1.09 (0.54–4.36) | 1.37 (0.92–4.09) |                   |
| Breast elasticity       |              |                   |                   | p-value\(^a\) |                   |                   |
| Mean (SD)               | 0.96 (0.15)  | 1.10 (0.20)       |                   | 1.57 (1.08)  | 2.03 (1.08)       |                   |
| Median (range)          | 0.96 (0.61–1.21) | 1.10 (0.74–1.58) |                   | 1.03 (0.52–3.85) | 1.32 (0.74–3.99) |                   |
| Breast viscosity        |              |                   |                   | p-value\(^a\) |                   |                   |
| Mean (SD)               | 0.23 (0.09)  | 0.23 (0.07)       |                   | 0.26 (0.27)  | 0.35 (0.24)       |                   |
| Median (range)          | 0.23 (0.08–0.39) | 0.23 (0.11–0.44) |                   | 0.20 (0.0–1.39) | 0.27 (– 0.05–1.05) |                   |
| BPE (#, % minimal or mild) | 14 (87.5%)  | 20 (58.8%)        |                   | 28 (90.3%)  | 35 (63.6%)        |                   |

Breast stiffness, elasticity, and viscosity were averaged across the left and right breasts.

\(^a\)For breast stiffness, elasticity, and viscosity, the \( p \)-value was based on a two-sample \( t \)-test allowing for unequal variances. For BPE, the \( p \)-value was based on Fisher’s exact test.
not significantly differ between the surgerized or biopsied breast versus contralateral breast (Table 3, Figs. 4 and 5).

In the multivariable logistic regression model, breast stiffness remained a significant predictor of risk status (OR = 4.26, 95% CI [1.96, 9.25]) even after controlling for breast density, MRI BPE, age, and menopausal status. Similar results were seen for breast elasticity (OR = 4.88, 95% CI [2.08, 11.43]) and viscosity (OR = 11.49, 95% CI [1.15, 114.89]).

**Discussion**

The most striking results in our prospective study to understand global breast stiffness in average and high-risk patients is the significantly higher stiffness of breast tissue in the high-risk (prior breast cancer history or high risk based on lifetime risk of greater than 20%) dense breasted patients compared to the average risk dense breasted patients. This finding held true even for the patients that had prior unilateral post-operative and/or post-treatment related radiation change as the affected/treated breast did not show a significant difference in MRE parameters between unaffected/untreated breast. Our study suggests that the structurally based (tissue stiffness) risk information obtained from MRE could be used to identify the subset of women with dense breasts most likely to benefit from increased surveillance and serve as a prognostic biomarker in screening breast cancer patients. These differences in stiffness were also seen...
between high-risk and average risk patients with non-dense breasts, although it is less clinically significant as the performance of screening mammography is better in non-dense breasts.

Through translational studies [27, 28], one biologic explanation for the increased risk of breast cancer in dense breast patients suggests that increased collagen deposition, tissue tensile strength and collagen structural differences may contribute to increased mammographic density, which then is associated with breast cancer initiation [4, 7, 14, 15]. In fact, increasing evidence indicates that the tumor microenvironment plays a critical role in regulating the biologic behavior of, and predisposition to breast cancer [36, 37]. Recent studies have shown that organization and stiffness of the collagen matrix are important in mediating tumor growth and invasion [3, 4, 28, 3, 4]. Abnormal changes in the amount and organization of extracellular matrix lead to altered biochemical, physical, and biomechanical properties of tumor-associated ECM that contribute to tumor progression [41, 42].

In a similar light, a 2002 study investigated the feasibility of MRE to distinguish malignant and benign properties of breast tissue. Analysis of MR elastograms using a 65 Hz frequency on 20 female patients with malignant and benign breast lesions and 15 healthy volunteers as the control demonstrated that cancerous growths consistently demonstrated higher elasticity values (greater stiffness) in contrast to surrounding tissue. In fact, quantitatively, the stiffness value of breast carcinomas was, on average, 418% higher than the value of the adjacent tissues ($p < 0.05$) [43]. Malignant breast tumors measured a median stiffness of 15.9 kPa, while adjacent breast parenchyma and fatty tissue measured a median of only 2.5 and 2.0 kPa, respectively. Furthermore, the difference in stiffness between malignant and benign tumors was also evident through MRE, where benign breast lesions were determined to be at a median value of 7.0 kPa. The differing values of malignant tumors, benign tumors, and surrounding breast tissue illustrate that MRE as an imaging technique has promise to differentiate between benign and malignant tumors.

**Fig. 4** Box and whisker plot of breast stiffness (averaged across the left and right breasts) by biopsy/surgery in high risk patients. 24 high-risk women with dense breasts and no biopsy/surgery and 30 high-risk women with dense breasts and biopsy/surgery in either or both breasts. The horizontal line within each box represents the median, and the diamond within each box represents the mean. The breast stiffness median = 1.34 versus 2.56 in the no biopsy/surgery versus biopsy surgery group. The breast stiffness mean = 1.92 versus 2.35 in the no biopsy/surgery versus biopsy surgery group. These means were not significantly different.
disease processes, and therefore demonstrates clinical value [43–45].

Clinically, we know that over 40% of our breast cancer screening patients have dense breasts [46]. As a result of relatively new dense breasts notification laws, these patients are now being told that they have dense breast tissue (which could result in decreased sensitivity of mammography screening and increase their risk of breast cancer). Providers are encouraged to discuss these details with patients and, where appropriate, offer various forms of supplemental dense breast screening [47–49]. These supplemental screening examinations can find additional cancers; however, they also result in increased false positive results [23, 50, 51]. Since the risks and benefits of a screening test are functions of each patient’s density features and risk factors, personal screening policies tailored to individuals are necessary and the new paradigm of breast cancer screening. Personalized breast cancer screening algorithms will result in cost efficiencies [52–57] and reduced false positive rates. As such, our data are promising, whereby imaging biomarker of global breast tissue stiffness could provide an additional component in a clinical decision-making tool to guide providers of screening and risk-reduction measures based on patient values and preferences.

In our study, we observed a nonsignificant increase in stiffness in both the dense and non-dense breasts. These observed differences with increasing stiffness with density are consistent with other smaller studies [58–60]; however the lack of a statistical significance is unique in our study. It should be noted that our study had few cases included along the extreme spectrum of breast densities, fatty \( n = 1 \) and extremely dense \( n = 3 \) in our average risk cohort, which may be affecting our results of statistical significance. Also, it should be noted in our study, that we chose to use the central slice as a first step to assess global 3D MRE values and used a 40 Hz frequency on a 3 T scanner. The region of interest included the central breast tissues, including fatty tissue and breast parenchyma on the slice, sparing the edges. This technique is similar to the annotations drawn and lessons learned on clinical diagnostic liver MRE. Contrast this technique to that of a 2017 study that demonstrated that dense breasts had significantly higher stiffness measurements compared with non-dense breasts \( p < 0.05 \) [60]) the authors used a 60 Hz frequency on the 3 T scanner, which requires less power for penetration. We speculate that
the stiffness is highly dependent on the measurement method and the tissues that are covered.

Limitations within our study highlight the need for further inquiry to fill the gaps of current research before implementation in clinical practice. Our study is one of the largest to date; other published breast MRE studies have been performed using a small sample cohort of approximately 20 to 50 patients, limiting the representation of breast tissue density. In addition, the high-risk volunteers used for testing the efficacy of MRE had included those with a personal history of breast cancer, making it difficult to extrapolate the results to the general screening population. Thus, future research should aim to encompass a larger set of patients to account for individual differences in breast tissue and a variety of lesion characteristics. Given the current study is based on self-reported family history of breast cancer rather than including patients who went on to develop breast cancer, in future trials, we will also plan to calculate lifetime and 5-year risks for patients based on accepted clinical breast cancer risk models [61–63] and follow patients who go on to develop breast cancer. Doing so will allow us to have more accurate correlations to lifetime risk rather than the current stratification provided here. Another limitation is the fairly homogenous demographics of the patient population in this study. Therefore, adding demographic variation to the population will be of utmost interest, given the variations seen in breast density based on racial differences [64–66]. Also, future studies should include computer-generated volumetric breast density from MG to classify patients as dense or non-dense, given the considerable inter- and intra-reader variability within the mammographic density reporting system [67, 68]. As MRE protocols continue to evolve and develop, standardized protocols with multi-institutional trials will be necessary to ensure generalizability of MRE results.

As a more personalized approach within the breast cancer screening regimen develops, further risk stratification using quantitative imaging biomarker of global breast stiffness could inform more effective personalized screening regimens. We anticipate the results of this study will give light to more investigations on how tissue stiffness correlates with breast cancer risk and prognosis. These prior studies and our results provide support for the further study of MRE given its ability to assess the viscoelastic properties of breast tumors and the surrounding tissue [69–71]. While the studies on MRE’s application to in vivo breast tissue are limited, this trial substantiates the capabilities of MRE and its potential for a risk stratification tool in women with dense breasts.

Conclusions

In conclusion, our work above suggests structurally based, quantitative biomarker of tissue stiffness obtained from global 3D breast MRE could provide a novel prognostic marker used to identify the subset of high-risk women with dense breasts. As such, a stiffness values could help stratify dense breast patients into those who are at elevated risk and would benefit from increased surveillance with supplemental imaging techniques and/or risk reduction measures.

Acknowledgements We would like to think the Mayo Clinic Cancer Center for providing grant funding for this study. We would also like to acknowledge the Women’s Health staff who have been instrumental with recruitment for this study and the breast imaging staff who helped with imaging patients using this new technology. Special thanks to Diana Almader-Smith, who assisted with formatting the references for this manuscript.

Author contributions All authors contributed to the study’s conception and design. Material preparation, data collection and analysis were performed by BKP, KP, KRB, and GM. The first draft of the manuscript was written by BKP, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding This study was funded by the Mayo Clinic Cancer Center MEGA grant.

Data availability The imaging data were stored on a shared internal drive between the authors. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Code availability N/A.

Declarations

Conflict of interest BKP has received unrelated grant funding from GRAIL Inc. and Hologic Inc. with monies directed to Mayo Clinic. Dr. Kay Pepin is an employee at Resoundant Inc. Dr. Jun Chen is an employee who holds patents and intellectual property at Resoundant Inc. Dr. Yuxiang Zhou holds intellectual property in interventional MRI. Dr. Northfelt has research funding with Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst) Dr. Anderson has Stock and Other Ownership Interests—FlexBioTech; SafeGen Therapeutics, Consulting or Advisory Role and research funding from Merck. Dr. Vachon does not have insurance, owns stock inexact sciences, receives research funding from grail, has intellectual property with breast density software algorithms and has received travel expenses from GRAIL Inc. Dr. Ehman owns stock, has research funding, and discloses uncompensated relationships with Resoundant. Dr. Swanson discloses Precision Oncology Insights Inc. Dr. Ehman and Mayo Clinic have financial interest and intellectual properties related to MR Elastography.

Ethical approval The study was approved by our research institutional review board. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Consent to participate Informed consent was obtained from all individual participants included in the study.

Consent for publication Patients signed informed consent regarding publishing their data. Previously presented at ASCO 2020: https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.10541

Acknowledgements

We would like to think the Mayo Clinic Cancer Center for providing grant funding for this study. We would also like to acknowledge the Women’s Health staff who have been instrumental with recruitment for this study and the breast imaging staff who helped with imaging patients using this new technology. Special thanks to Diana Almader-Smith, who assisted with formatting the references for this manuscript.

Author contributions All authors contributed to the study’s conception and design. Material preparation, data collection and analysis were performed by BKP, KP, KRB, and GM. The first draft of the manuscript was written by BKP, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding This study was funded by the Mayo Clinic Cancer Center MEGA grant.

Data availability The imaging data were stored on a shared internal drive between the authors. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Code availability N/A.

Declarations

Conflict of interest BKP has received unrelated grant funding from GRAIL Inc. and Hologic Inc. with monies directed to Mayo Clinic. Dr. Kay Pepin is an employee at Resoundant Inc. Dr. Jun Chen is an employee who holds patents and intellectual property at Resoundant Inc. Dr. Yuxiang Zhou holds intellectual property in interventional MRI. Dr. Northfelt has research funding with Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst) Dr. Anderson has Stock and Other Ownership Interests—FlexBioTech; SafeGen Therapeutics, Consulting or Advisory Role and research funding from Merck. Dr. Vachon does not have insurance, owns stock inexact sciences, receives research funding from grail, has intellectual property with breast density software algorithms and has received travel expenses from GRAIL Inc. Dr. Ehman owns stock, has research funding, and discloses uncompensated relationships with Resoundant. Dr. Swanson discloses Precision Oncology Insights Inc. Dr. Ehman and Mayo Clinic have financial interest and intellectual properties related to MR Elastography.

Ethical approval The study was approved by our research institutional review board. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Consent to participate Informed consent was obtained from all individual participants included in the study.

Consent for publication Patients signed informed consent regarding publishing their data. Previously presented at ASCO 2020: https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.10541
References

1. Boyd NF, Lockwood GA, Byng JW, Trichtcher DL, Yaffe MJ (1998) Mammographic densities and breast cancer risk. Cancer Epidemiol Prev Biomark 7(12):1133–1144
2. Vachon CM, Brandt KR, Ghosh K et al (2007) Mammographic breast density as a general marker of breast cancer risk. Cancer Epidemiol Prev Biomark 16(1):43–49
3. Acerbi I, Cassereau L, Dean I et al (2015) Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. Integr Biol (Camb) 7(10):1120–1134
4. Levental KR, Yu H, Kass L et al (2009) Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139(5):891–906
5. McConnell JC, O’Connell OV, Brennan K et al (2016) Increased peri-ductal collagen micro-organization may contribute to raised mammographic density. Breast Cancer Res 18(1):5
6. Moom JK, Ou G, Weaver VM (2014) Extracellular matrix assembly: a multiscale deconstruction. Nat Rev Mol Cell Biol 15(12):771–785
7. Ghosh K, Brandt KR, Reynolds C et al (2012) Tissue composition of mammographically dense and non-dense breast tissue. Breast Cancer Res Treat 131(1):267–275
8. Martin LJ, Boyd NF (2008) Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. Breast Cancer Res 10(1):1–14
9. Martin LJ, Boyd N (2008) Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. Breast Cancer Res 10(1):1–14
10. Bruix J, Sherman M, Llovet JM et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421–430
11. Hoyt K, Castaneda B, Zhang M et al (2008) Tissue elasticity properties as biomarkers for prostate cancer. Cancer Biomark 4(4–5):213–225
12. Tuxhorn JA, Ayala GE, Rowley DR (2001) Reactive stroma in prostate cancer progression. J Urol 166(6):2472–2483
13. Provenzano PP, Inman DR, Eliceiri KW et al (2008) Collagen density promotes mammary tumor initiation and progression. BMC Med 6:11
14. Kaushik S, Pickup MW, Weaver VM (2016) From transformation to metastasis: deconstructing the extracellular matrix in breast cancer. Cancer Metastasis Rev 35(4):655–667
15. Northey JJ, Barrett AS, Acerbi I et al (2020) Stiff stroma increases breast cancer risk by inducing the oncogene ZNF217. J Clin Invest 130(11):5721–5737
16. Glaser KJ, Manduca A, Ehmam RL (2012) Review of MR elastography applications and recent developments. JMRI 36(4):757–774
17. Manduca A, Oliphant TE, Dresner MA et al (2001) Magnetic resonance elastography: non-invasive mapping of tissue elasticity. Med Image Anal 5(4):237–254
18. Marniappan YK, Glaser KJ, Ehmam RL (2010) Magnetic resonance elastography: a review. Clin Anat 23(5):497–511
19. Muthupillai R, Lomas DJ, Rossman PJ, Greenleaf JF, Manduca A, Ehmam RL (1995) Magnetic resonance elastography by direct visualization of propagating acoustic strain waves. Science (New York, NY) 269(5232):1854–1857
20. Mann RM, Balleyguier C, Baltzer PA et al (2015) Breast MRI: EUSOBI recommendations for women’s information. Eur Radiol 25(12):3669–3678
21. Monticciolo DL, Newell MS, Moy L, Niell B, Monsees B, Sickles EA (2018) Breast cancer screening in women at higher-than-average risk: recommendations from the ACR. J Am Coll Radiol 15:408–414
22. Sardanelli F, Boetes C, Borisch B et al (2010) Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer 46(8):1296–1316
23. Saslow D, Boetes C, Burke W et al (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57(2):75–89
24. Patel BK, Samreen N, Zhou Y et al (2020) MR elastography of the breast: evolution of technique, case examples, and future directions. Clin Breast Cancer 21:102
25. O’Flynn EAM, deSouza NM (2011) Functional magnetic resonance: biomarkers of response in breast cancer. Breast Cancer Res 13(1):204
26. ACR BI-RADS (2013) Atlas: breast imaging reporting and data system. 5th ed. Reston: American College of Radiology
27. Butcher DT, Alliston T, Weaver VM (2009) A tense situation: forcing tumour progression. Nat Rev Cancer 9(2):108–122
28. Conklin MW, Eickhoff JC, Riching KM et al (2011) Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am J Pathol 178(3):1221–1232
29. Bartow SA, Pathak DR, Mettler FA, Key CR, Pike MC (1995) Breast mammographic pattern: a concatenation of confounding and breast cancer risk factors. Am J Epidemiol 142(8):813–819
30. Boyd NF, Jensen HM, Cooke G, Han HL (1992) Relationship between mammographic and histological risk factors for breast cancer. J Natl Cancer Inst 84(15):1170–1179
31. Gabrielson M, Chiesa F, Paulsson J et al (2016) Amount of stroma is associated with mammographic density and stromal expression of oestrogen receptor in normal breast tissues. Breast Cancer Res Treat 158(2):253–261
32. Hawes D, Downey S, Pearce CL et al (2006) Dense breast tumour stroma shows greatly increased concentration of breast epithelium but no increase in its proliferative activity. Breast Cancer Res 8(2):R24
33. Huo CW, Chew G, Hill P et al (2015) High mammographic density is associated with an increase in stromal collagen and immune cells within the mammary epithelium. Breast Cancer Res Treat 17(1):79
34. Li T, Sun L, Miller N et al (2007) The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. Cancer Epidemiol Biomarkers Prev 16(2):343–349
35. Turashvili G, McKinney S, Martin L et al (2009) CMMN: Breast cancer progressing to carcinoma. Am J Pathol 178(3):1221–1232
36. Butcher DT, Alliston T, Weaver VM (2009) Tumor-extracellular matrix interactions: identification of tools associated with breast cancer progression. Semin Cancer Biol 21:102
37. Madrzone R, Montori VM, Sias H et al (2007) Association between mammographic density and breast cancer risk factors. Am J Epidemiol 142(8):813–819
38. Patel BK, Samreen N, Zhou Y et al (2020) MR elastography of the breast: evolution of technique, case examples, and future directions. Clin Breast Cancer 21:102
enhanced MRI of the breast by combined quantitative and qualitative analysis. Br J Radiol 71(845):501–509
43. Lorenzen J, Sinkus R, Lorenzen M et al (2002) MR elastography of the breast: preliminary clinical results. RoFo 174(7):830–834
44. Sinkus R, Siegmann K, Xydeas T, Tanter M, Claussen C, Pink M (2007) MR elastography of breast lesions: understanding the solid/liquid duality can improve the specificity of contrast-enhanced MR mammography. Magn Reson Med 58(6):1135–1144
45. Xydeas T, Siegmann K, Sinkus R, Krainick-Strobel U, Miller S, Claussen CD (2005) Magnetic resonance elastography of the breast: correlation of signal intensity data with viscoelastic properties. Invest Radiol 40(7):412–420
46. Sprague BL, Gangnon RE, Burt V et al (2014) Prevalence of mammographically dense breasts in the United States. J Natl Cancer Inst. https://doi.org/10.1093/jnci/dju255
47. Berg WA (2016) Current status of supplemental screening in dense breasts. J Clin Oncol 34(16):1840–1843
48. Throckmorton AD, Rhodes DJ, Hughes KS, Degnim AC, Dickson-Witmer D (2016) Dense breasts: what do our patients need to be told and why? Ann Surg Oncol 23(10):3119–3127
49. Vourtsis A, Berg WA (2019) Breast density implications and supplemental screening. Eur Radiol 29(4):1762–1777
50. Lee CH, Dershaw DD, Kopans D et al (2010) Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol 7(1):18–27
51. Tagliafico AS, Calabrese M, Mariscotti G et al (2016) Adjunct screening with tomosynthesis or ultrasound in women with mammography-negative dense breasts: interim report of a prospective comparative trial. J Clin Oncol 34(16):1882–1888
52. Chin L, Andersen JN, Futreal PA (2011) Cancer genomics: from discovery science to personalized medicine. Nat Med 17(3):297–303
53. Hamburg MA, Collins FS (2010) The path to personalized medicine. N Engl J Med 363(4):301–304
54. Keen JD (2011) Analysis of health benefits and cost-effectiveness of mammography for breast cancer. Ann Intern Med 155(8):566; author reply 566-567
55. Jud SM, Häberle L, Fasching PA et al (2012) Correlates of mammographic density in B-mode ultrasound and real time elastography. Eur J Cancer Prev 21(4):343–349
56. Li X, Wang JN, Fan ZY et al (2015) Determination of the elasticity of breast tissue during the menstrual cycle using real-time shear wave elastography. Ultrasound Med Biol 41(12):3140–3147
57. Pepin KM, Ehman RL, McGee KP (2015) Magnetic resonance elastography (MRE) in cancer: technique, analysis, and applications. Prog Nucl Magn Reson Spectrosc 90–91:32–48
58. Chen JH, Chan S, Zhang Y, Li S, Chang RF, Su MY (2019) Evaluation of breast stiffness measured by ultrasound and breast density measured by MRI using a prone-supine deformation model. Biomark Res 7:20
59. Golatta M, Schweitzer-Martin M, Harcos A et al (2013) Normal breast tissue stiffness measured by a new ultrasound technique: virtual touch tissue imaging quantification (VTIQ). Eur J Radiol 82(11):e676-679
60. Hawley JR, Kalra P, Mo X, Raterman B, Yee LD, Kolipaka A (2017) Quantification of breast stiffness using MR elastography at 3 Tesla with a soft sternal driver: a reproducibility study. J Magn Reson Imaging 45(5):1379–1384
61. Armstrong K, Eisen A, Weber B (2000) Assessing the risk of breast cancer. N Engl J Med 342(8):564–571
62. Brentnall AR, Cohn WF, Knaus WA, Yaffe MJ, Cuzick J, Harvey JA (2019) A case-control study to add volumetric or clinical mammographic density into the Tyrer-Cuzick breast cancer risk model. J Breast Imaging 1(2):99–106
63. Tice JA, Cummings SR, Ziv E, Kerlikowske K (2005) Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat 94(2):115–122
64. del Carmen MG, Halpern EF, Kopans DB et al (2007) Mammographic breast density and race. Am J Roentgenol 188(4):1147–1150
65. McCarthy AM, Keller BM, Pantalone LM et al (2016) Racial differences in quantitative measures of area and volumetric breast density. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djw104
66. Razzaghi H, Troester MA, Gierach GL, Olshan AF, Yankaskas BC, Millikan RC (2012) Mammographic density and breast cancer risk in White and African American Women. Breast Cancer Res Treat 135(2):571–580
67. Gard CC, Aiello Bowles EJ, Miglioretti DL, Taplin SH, Rutter CM (2015) Misclassification of Breast Imaging Reporting and Data System (BI-RADS) mammographic density and implications for breast density reporting legislation. Breast J 21(5):481–489
68. Redondo A, Comas M, Macià F et al (2012) Inter- and intra-radiologist variability in the BI-RADS assessment and breast density categories for screening mammograms. Br J Radiol 85(1019):1465–1470
69. Balleyguier C, Lakhdar AB, Dunant A, Mathieu MC, Delaloge S, Sinkus R (2018) Value of whole breast magnetic resonance elastography added to MRI for lesion characterization. NMR Biomed 31(1):e3795
70. McKnight AL, Kugel JL, Rossman PJ, Manodu A, Hartmann LC, Ehman RL (2002) MR elastography of breast cancer: preliminary results. Am J Roentgenol 178(6):1411–1417
71. Sinkus R, Lorenzen J, Schrader D, Lorenzen M, Dargatz M, Holz D (2000) High-resolution tensor MR elastography for breast tumour detection. Phys Med Biol 45(6):1649–1664

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.